{"transactions":[{"id":746351,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:37:53.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":2625,"price":10.73,"value":28166.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9767,"source":{"system":"sec-edgar","filing":"0001808296-26-000004","document":"form4-06082026_080648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000180829626000004/form4-06082026_080648.xml","form_type":"4"}},{"id":748117,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:15:20.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":7433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":7433,"derivative":{"exercise_price":10.5,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":7433},"source":{"system":"sec-edgar","filing":"0001808296-26-000002","document":"form4-06052026_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000180829626000002/form4-06052026_040603.xml","form_type":"4"}},{"id":748116,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:15:20.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":7142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":12392,"source":{"system":"sec-edgar","filing":"0001808296-26-000002","document":"form4-06052026_040603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000180829626000002/form4-06052026_040603.xml","form_type":"4"}},{"id":1119806,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:15:17.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10500,"derivative":{"exercise_price":14.82,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001415889-25-015973","document":"form4-06062025_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588925015973/form4-06062025_040604.xml","form_type":"4"}},{"id":1119805,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:15:17.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":5250,"source":{"system":"sec-edgar","filing":"0001415889-25-015973","document":"form4-06062025_040604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588925015973/form4-06062025_040604.xml","form_type":"4"}},{"id":1495236,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-03T20:15:06.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":46.31,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-015150","document":"form4-06032024_040602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588924015150/form4-06032024_040602.xml","form_type":"4"}},{"id":1546832,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:41.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":750000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":6.78,"expiration_date":"2033-02-10","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001415889-24-010433","document":"form4-04052024_040430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588924010433/form4-04052024_040430.xml","form_type":"4"}},{"id":1546831,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:41.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":10.03,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001415889-24-010433","document":"form4-04052024_040430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588924010433/form4-04052024_040430.xml","form_type":"4"}},{"id":1546830,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:41.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":275000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":35.38,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001415889-24-010433","document":"form4-04052024_040430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588924010433/form4-04052024_040430.xml","form_type":"4"}},{"id":1546829,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:41.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":437413,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount."}],"balance_after":0,"derivative":{"exercise_price":5.63,"expiration_date":"2030-08-18","underlying":"Common Stock","underlying_shares":437413},"source":{"system":"sec-edgar","filing":"0001415889-24-010433","document":"form4-04052024_040430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588924010433/form4-04052024_040430.xml","form_type":"4"}},{"id":1546828,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-05T20:55:41.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1281642,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled  pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option."}],"balance_after":0,"derivative":{"exercise_price":2.57,"expiration_date":"2030-03-23","underlying":"Common Stock","underlying_shares":1281642},"source":{"system":"sec-edgar","filing":"0001415889-24-010433","document":"form4-04052024_040430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588924010433/form4-04052024_040430.xml","form_type":"4"}},{"id":1546827,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-04-05T20:55:41.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2186,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-010433","document":"form4-04052024_040430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000141588924010433/form4-04052024_040430.xml","form_type":"4"}},{"id":1862544,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T20:38:47.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":48.79,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-035441","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000120919123035441/doc4.xml","form_type":"4"}},{"id":2013714,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-15T16:01:38.000Z","date":"2023-02-10","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the \"Vesting Commencement Date\") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":750000,"derivative":{"exercise_price":6.78,"expiration_date":"2033-02-10","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001209191-23-009620","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000120919123009620/doc4a.xml","form_type":"4/A","original_submission_date":"2023-02-14"}},{"id":2016721,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-14T22:00:33.000Z","date":"2023-02-10","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the \"Vesting Commencement Date\") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":215000,"derivative":{"exercise_price":6.78,"expiration_date":"2033-02-10","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001209191-23-009204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000120919123009204/doc4.xml","form_type":"4"}},{"id":2245010,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-06-03T20:24:38.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8293,"derivative":{"exercise_price":32.95,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-22-034042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000120919122034042/doc4.xml","form_type":"4"}},{"id":2394691,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-15T21:00:45.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the \"Vesting Commencement Date\") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":400000,"derivative":{"exercise_price":10.03,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-22-009740","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000120919122009740/doc4.xml","form_type":"4"}},{"id":2683615,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-03T21:29:11.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be\nfully vested on the date of Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through\neach such date."}],"balance_after":8293,"derivative":{"exercise_price":51.48,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-21-037790","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000120919121037790/doc4.xml","form_type":"4"}},{"id":2859537,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2021-02-16T22:54:52.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests and becomes exercisable over time at the following rate: 1/48th of the total number of shares subject to the Option shall vest each month in equal installments starting on March 1, 2021."}],"balance_after":275000,"derivative":{"exercise_price":35.38,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001209191-21-010892","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000120919121010892/doc4.xml","form_type":"4"}},{"id":3130849,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":25934,"kind":"person","name":"Farzan Nima","position":1,"cik":"0001808296","reported_name":"Farzan Nima","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-29T21:19:32.000Z","date":"2020-05-29","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on each of June 2, 2020, September 2, 2020, December 2, 2020 and March 2, 2021, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8500,"derivative":{"exercise_price":28.74,"expiration_date":"2030-05-29","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-20-032991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808296/000120919120032991/doc4.xml","form_type":"4"}}]}